Do topical calcineurin inhibitors treat morphea?

Morphea, also called localised scleroderma, causes areas of skin to become firm, tight or changed in colour. A topical calcineurin inhibitor reduces local immune activity without being a corticosteroid. It may be discussed when inflammation is near the surface or when a sensitive site needs careful treatment. It may not reach deeper hardened tissue, and it does not reverse every established change in texture or movement.

The appearance of a patch can change while the disease is active. A clinician may look for a lilac-coloured edge, increasing firmness, extension into nearby skin or restriction across a joint. These findings help determine whether a cream is suitable or whether another approach is needed.

Arrange a dermatology assessment before starting a prescription cream on a suspected morphea patch. Use the medicine only on the areas and schedule advised, and apply it gently to clean, dry skin. Do not cover the area with an occlusive dressing unless instructed. Take occasional photographs in similar lighting so changes in colour, firmness and size are easier to describe.

Ask whether the lesion appears superficial or deep, whether treatment should include moisturising, and how progress will be checked. Tell the clinician about pregnancy, breastfeeding, other skin medicines and any history of skin infection.

Seek prompt medical advice if a patch is rapidly expanding, becomes painful, breaks down, drains, or limits movement near a joint. Arrange assessment sooner if the face, scalp, eyes or a large body area is involved, or if a child has a new enlarging lesion. A new firm patch should be examined because several skin conditions can resemble morphea.

Could this patch be superficial morphea, and how will you judge whether it is active? Would a topical calcineurin inhibitor suit its location and depth? What signs should make me stop the medicine or contact you? How will you monitor response and scarring?